FDMT Q4 2023 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

-$19,000-101.5% YoY

Gross Profit

-$26M137089.5% margin

Operating Income

-$37M192905.3% margin

Net Income

-$32M169910.5% margin

EPS (Diluted)

$-0.83

QoQ Revenue Growth

-100.1%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$340M

Total Liabilities

$32M

Stockholders' Equity

$308M

Cash & Equivalents

$249M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	-$19,000	$1M	-101.5%
Gross Profit	-$26M	-$20M	-28.6%
Operating Income	-$37M	-$29M	-27.6%
Net Income	-$32M	-$27M	-17.9%

Geographic Segments

NETHERLANDS

$1,000100%